Compare NSPR & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | AYTU |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 27.4M |
| IPO Year | 2009 | 2015 |
| Metric | NSPR | AYTU |
|---|---|---|
| Price | $0.85 | $2.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 75.5K | 27.3K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,310,000.00 | ★ $27,632,080.00 |
| Revenue This Year | $57.98 | N/A |
| Revenue Next Year | $95.41 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.63 | $1.65 |
| 52 Week High | $2.57 | $3.07 |
| Indicator | NSPR | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 57.47 |
| Support Level | $0.66 | $2.08 |
| Resistance Level | $1.04 | $2.46 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 54.65 | 67.65 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.